Unlocking the Power of Gene Therapy: Cellectis to Share Exciting Findings on TALE Base Editors and Non-Viral Techniques at ESGCT’s 31st Annual Congress
Exciting Developments in Gene-Editing Technology Introducing Cellectis NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) — Cellectis, a clinical-stage biotechnology company known for using its pioneering gene-editing platform to develop cutting-edge cell and gene therapies, has recently announced some groundbreaking developments. The Company will be showcasing pre-clinical data at the European Society of Cell and Gene…